Igea Med
On 18 December 2020, Igea Med S.p.A. obtained admission to negotiate ordinary shares on AIM Italia, a multilateral negotiations system organized and managed by Borsa Italiana. Negotiations began on 22 December 2020.
Integrae SIM acted as Nomad and Global Coordinator.
The equivalent of the placement of a total of 259,000 shares and at the start date of the negotiations on AIM Italia PRO, the share capital of Igeamed S.p.A. will be represented by a total of 2,259,000 ordinary shares with a float of 11.47% for a planned capitalization equal to € 3,388,500.
The enterprise. Igeamed, a company of the Igeam Group, operates in the market of medicine for companies and provides companies with integrated consulting and engineering services for risk management and human resources. Igeamed, which operates entirely in Italy through a capillary structure with four operational headquarters throughout the country and, in particular, in Bari, Rome, Ravenna, and Milan, aims to promote corporate healthcare, representing the ideal partner to address the new needs of companies increasingly oriented towards social responsibility and the overall well-being of employees and the company system as a whole.
Ultima Ricerca Igea Med
BREAKING NEWS| In the press release dated August 7, 2025, Litix SpA, an Innovative SME that combines art, technology, tradition, and innovation through three business units offering solutions ranging from the design and production of robotic cells for marble and other materials, to the creation of sculptures and other artistic and design works, to hardware and software development for additive manufacturing and other advanced processes, announced that its subsidiary Aivox Srl will take part, as an industrial partner, in the national research project “More4Neuro – Multi-material 3D Printing for Education in Neurosurgery.” The initiative, led by the University of Milan within the framework of the Partenariati Estesi – HealthTech program, aims to develop next-generation simulators for medical and neurosurgical training, capable of accurately replicating the tactile, mechanical, and structural properties of brain tissues through multimaterial additive manufacturing technologies. Aivox, specialized in computational design, software development, additive manufacturing, and multimaterial 3D printing, will contribute its expertise by taking responsibility for the design of physical models, definition of production processes, and validation of prototypes through iterative development and clinical testing phases. The activities assigned to Aivox have a total value of € 0.68 million, of which € 0.54 million will be covered by public funding. This project marks another step in the strategy outlined in the latest annual report, in which Litix emphasized the importance of diversifying its portfolio with highly innovative projects and strengthening its position in advanced technology markets, based on the belief that technological development and global presence are the key growth drivers in the medium term. Following a transitional year in 2024, which marked the first full year of Aivox’s operations, the participation in More4Neuro confirms the Group’s ability to seize opportunities in high-potential sectors, expanding the intersection between digital manufacturing and specialized education. Considering the information disclosed in the press release, we confirm our recommendation: Target Price € 2.50, BUY Rating and MEDIUM Risk. |
